Drug Trial Radar · NCT05163223
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10
Actual
Start
Feb 28, 2022
Primary completion
May 31, 2024
Study completion May 31, 2024
Sponsor
- Lead sponsor
- Aston Sci. Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of an adjuvant treatment of therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in patients with HER2-low expression (IHC 1+ or 2+ and ISH-) and hormone receptor-negative(ER-, PR-) breast cancer with residual disease after neoadjuvant treatment. Patients will be randomized 1:1 to either the Experimental arm (combination of AST-301/rhuGM CSF and standard adjuvant therapy) or the Control arm (combination of placebo/rhuGM CSF and standard adjuvant therapy). Standard adjuvant chemotherapy will be pembrolizumab or capecitabine. Adjuvant therapy will be administered in compliance with the NCCN guideline for breast cancer (Version 8, 2021), and IP (AST-301) will be administered 3 times every 3 weeks in the adjuvant treatment period, with a booster administered at 24 weeks (±7 days) post the third dose of IP administration. Survival follow up will be performed to determine invasive Disease Free survival(iDFS).
Conditions
- Breast Cancer
Interventions
AST-301(pNGVL3-hICD)Biological
Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
rhuGM-CSFDrug
Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
PlaceboDrug
Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
PembrolizumabDrug
Q3W; IV infusion
CapecitabineDrug
On days 1-14 (Q3W), BID ; Oral administration,
Primary outcomes
What the sponsor says the trial is designed to measure.
- 2-year invasive disease free survival rate (iDFS)Time frame: Overall study period approximately up to 4years (End of study in this study is defined as 2years frm the date of last Patient In.
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers
Chandler, Arizona
Scripps Health
La Jolla, California
Moffitt Cancer Center
Tampa, Florida
University of Illinois Cancer Center
Chicago, Illinois
Nebraska Cancer Specialist
Omaha, Nebraska
Gabrail Cancer Center Research
Canton, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Toledo Clinic Cancer Center
Toledo, Ohio
Providence Cancer Institute
Portland, Oregon
University of Washington
Seattle, Washington
Changhua Christian Hospital
Changhua, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
China Medical University Hospital
Taichung, Taiwan
Chi Mei Medical Center
Tainan, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.